COMP <GO>
HCA vs MRK // PIOTROSKI F-SCORE QUALITY
HCA Healthcare Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: HCA 7
— MRK 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: HCA
LAST: $473.19 (-1.02%) • MKT CAP: $103.51B
piotroski-score
8/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | 20.70% | -1.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.5x | 15.3x | -3.80 | HCA | /valuation <GO> |
| Free Cash Flow Yield | 7.43% | 3.42% | +4.01 | HCA | /fcf-yield <GO> |
| Operating Margin | 10.90% | 34.30% | -23.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 28.10% | -19.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 7.10% | 1.30% | +5.80 | HCA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 2.26% | -1.60 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.68 | 5.19 | -1.51 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 7/9 | +1.00 | HCA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.60% | +0.40 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.7 | 56.9 | +3.83 | HCA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.92 | +0.12 | HCA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 14.2x | 18.4x | -4.20 | HCA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $103.51B | $361.02B | -$257.52B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCA REV | MRK REV | HCA GROSS % | MRK GROSS % | HCA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.60B | $65.01B | 44.0% | 74.8% | $7.69B | $12.36B |
| FY 2024 | $70.60B | $64.17B | 44.0% | 76.3% | $5.64B | $18.10B |
| FY 2023 | $64.97B | $60.12B | 44.0% | 44.0% | $6.51B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCA // BETA 1.04
MRK // BETA 0.92